This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders USA
RNA breakthroughs, Case Studies and Partnerships
September 10-11, 2025Boston Exhibition & Convention Center, USA

Investor Registration

Qualified Investors* receive complimentary registration to RNA Leaders USA, providing unparalleled access to the most promising RNA therapeutics and vaccine innovators in one concentrated event.

Why Leading Investors Choose RNA Leaders USA

As a qualified investor, you'll receive:

  • Complimentary Full Access Pass ($2,999 value)

  • Priority scheduling in the partnering system

  • Early access to the complete attendee list

  • Invitation to exclusive networking functions with C-suite executives

Strategic Value:

  • Direct Access to Tomorrow's Breakthroughs - Connect with 350+ senior decision-makers from emerging biotechs and established pharma companies developing the next generation of RNA therapeutics

  • Efficient Deal Flow - Leverage the partneringONE platform to pre-schedule high-quality meetings with companies aligned to your investment thesis

  • Competitive Intelligence - Gain insider perspectives on emerging technologies, clinical developments, and market trends shaping the RNA landscape

  • Portfolio Company Opportunities - Identify potential collaborations, partnerships, and exit strategies for your existing portfolio companies


*Qualified investors include venture capital, private equity, family offices, angel investors, and corporate venture funds actively investing in life sciences. Complimentary registration requires participation in at least two one-on-one partnering meetings with life science companies.

Attendees who do not qualify for complimentary registration include:

  1. Executives who invest personal, disposable income, who's salaried occupation is not that of a full time investor (i.e. not individual Angels).
  2. Firms who offer advisory or consulting services of any nature.
  3. Firms who offer brokerage services of any nature.
  4. Crowd funding platforms.
  5. Service providers/consultants to the biotech industry.
  6. Biotech/ life sciences company employee or product suppliers to the biotech industry including CRO’s and CMO’s.
  7. Firms that provide services and/or charge a fee to biotech companies in exchange for research/media/investor relations coverage.
  8. Retail/individual investors.
  9. Investment and merchant bankers.
  10. Real estate development professionals.
  11. Members of economic development organizations.
  12. Firms who have a service providing component to their fund’s business model will be evaluated on a case by case basis. If this fund’s information is NOT located in any mainstream database (Ipreo, FactSet), LSX may ask for references for investor qualification.

RNA Leaders USA reserves the right, in its sole discretion, to make the determination of the proper classification of an investor or registrant. Depending on this classification, registration fees may be required.

RNA Leaders USA reserves the right to publish materials and restrict conference and/or partnering system access consistent with these determinations.